Navigation Links
AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference

CASTLE ROCK, Colo., Aug. 29 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, reported today the company has been invited to present at the annual Roth Capital Partners New York Investor Conference to be held September 5 and 6, 2007. More than 1,200 institutional investors are expected to attend the conference, which will be held at the Westin New York at Times Square.

AspenBio's CEO Richard Donnelly is scheduled to present on Thursday, September 6, at 2:00 P.M. Eastern Time. A simultaneous Webcast will be available at:

Mr. Donnelly will discuss progress of AspenBio key products, including a specialized assay that detects a marker in the blood associated with appendicitis. According to three studies conducted during the past 33 months, including an ongoing 400 patient study, the company's AppyScore(TM) blood test has been able to identify patients with appendicitis at a very high sensitivity level of 94% to 97%. This compares to significantly lower diagnostic success rates for expensive CT scans, which are generally considered the best diagnostic method currently available for appendicitis. With the AppyScore emergency room triage test and its sister product, AppyScreen(TM), designed for physician offices, AspenBio is targeting a significant need for more economical, accurate and faster assessment of the appendicitis condition.

Roth Capital Partners Stock Conferences are among the largest in the nation for micro and small-cap companies in the technology, healthcare, financial services and consumer products sectors. For more information on the conference, please visit the conference website at, or call the conference desk at (800) 678-9147. For media inquiries and press credentials only, call (949) 720-5700.

About Roth Capital Partners, LLC

Since 1984, Roth Capital Partners has been a leader and innovator in the small and micro cap markets. Roth provides the full spectrum of investment banking services, including raising capital, research coverage, creating liquidity, trading and market making, merger and acquisition advisory services, sales support, and investor conferences. Visit for more information.

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to make exciting progress in the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients complaining of abdominal pain. For more information, please visit:


Scott Liolios or Ron Both

Liolios Group, Inc.

(949) 574-3860

SOURCE AspenBio Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Park Systems , world ... scanning ion conductance microscopy module to Park NX10 that is the only product ... SICM benefits virtually all materials characterization that require measurements in liquid such as ...
(Date:12/1/2015)... Texas (PRWEB) , ... December ... ... , a leading relationship marketing company specializing in scientifically backed, age-defying products, ... January 2016 issue, which highlights the exponential success and unrivaled opportunities that ...
(Date:12/1/2015)... Calif. , Dec. 1, 2015 Cepheid ... of its participation at the Piper Jaffray Healthcare Conference ... this morning, the Company is reaffirming its outlook for ... for 2016, in addition to discussing longer term business ... and Chief Executive Officer.  "We continue to be the ...
(Date:12/1/2015)... ... December 01, 2015 , ... The American Society of Gynecologic ... Kyle Mathews will join fellow surgeons in the shared pursuit of “advancing ... experienced urogynecologist, founder of Plano Urogynecology Associates and Fellow of the American ...
Breaking Biology Technology:
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... JOLLA, Calif. , Oct. 29, 2015  The ... a new report titled, "DNA Synthesis and Biosecurity: Lessons ... well the Department of Health and Human Services guidance ... issued in 2010. --> ... but it also has the potential to pose unique ...
Breaking Biology News(10 mins):